Factor Xa inhibitors for acute coronary syndromes (Q24234760)

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in coll

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 200

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Acute Coronary Care in the Elderly, Part I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Ger

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Factor Xa inactivation in acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Fondaparinux sodium: a review of its use in the management of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Antithrombotics in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acut

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

The pathophysiology of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Heparin-induced thrombocytopenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

A classification of unstable angina revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Beyond unfractionated heparin and warfarin: current and future advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

New anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Review of the treatment of acute coronary syndrome in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007038.PUB2